Acrivon Begin Period Cash Flow from 2010 to 2025
| ACRV Stock | 6.07 0.28 4.84% |
Begin Period Cash Flow | First Reported 2010-12-31 | Previous Quarter 34.4 M | Current Value 36.8 M | Quarterly Volatility 26.2 M |
Check Acrivon Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acrivon Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 479.9 K, Selling General Administrative of 25.5 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.85. Acrivon financial statements analysis is a perfect complement when working with Acrivon Therapeutics, Valuation or Volatility modules.
Acrivon | Begin Period Cash Flow |
Latest Acrivon Therapeutics,'s Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Acrivon Therapeutics, Common over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Acrivon Therapeutics,'s Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acrivon Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Acrivon Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 14,011,686 | |
| Geometric Mean | 4,211,321 | |
| Coefficient Of Variation | 187.31 | |
| Mean Deviation | 18,130,154 | |
| Median | 1,919,000 | |
| Standard Deviation | 26,245,959 | |
| Sample Variance | 688.9T | |
| Range | 98.1M | |
| R-Value | 0.57 | |
| Mean Square Error | 498.3T | |
| R-Squared | 0.32 | |
| Significance | 0.02 | |
| Slope | 3,141,683 | |
| Total Sum of Squares | 10332.8T |
Acrivon Begin Period Cash Flow History
About Acrivon Therapeutics, Financial Statements
Acrivon Therapeutics, investors use historical fundamental indicators, such as Acrivon Therapeutics,'s Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Acrivon Therapeutics,. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 34.4 M | 36.8 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.